Puretech founded entity vedanta announces positive topline phase 2 data for ve303 in high-risk c. difficile infection and exercise of $23.8 million option by barda

Boston--(business wire)--puretech founded entity vedanta announces positive topline phase 2 data for ve303 in high-risk c. difficile and exercise of $23.8m option by barda

PRTC Ratings Summary

PRTC Quant Ranking